中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 12
Dec.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(12): 2441-2449

Risk factors for liver cancer in chronic hepatitis B patients and construction of a nomogram prediction model

DOI: 10.12449/JCH241214
  • 1.

    Department of Epidemiology/Key Laboratory of Public Health Safety，Ministry of Education，School of Public Health，Fudan University，Shanghai 200032，China

  • 2.

    Department of Infection Management，Qidong Third People’s Hospital，Qidong，Jiangsu 226200，China

  • 3.

    Department of Scientific Research，Qidong People’s Hospital/Qidong Liver Cancer Institute/Affiliated Qidong Hospital of Nantong University，Qidong，Jiangsu 226200，China

Research funding:

National Key Research and Development Program of China (2021YFC2500405)

More Information
  • Corresponding author: ZHANG Tiejun， tjzhang@shmu.edu.cn （ORCID： 0000-0002-5187-7393）
  • Received Date: 2024-04-02
  • Accepted Date: 2024-05-23
  • Published Date: 2024-12-25
    Abstract
  •   Objective   To investigate the risk factors for liver cancer in patients with chronic hepatitis B （CHB） in the Qidong Chronic Hepatitis B cohort， and to construct a nomogram model for predicting the risk of liver cancer in CHB patients.   Methods   A structured questionnaire survey was conducted among the CHB patients， aged ≥18 years， who attended the outpatient service of Qidong Third People’s Hospital from January 1 to December 31， 2016. The onset of liver cancer was defined as the primary outcome， and the outcomes of the cohort were obtained from Qidong Cancer Registry. Baseline clinical features were compared；between the liver cancer group and the non-liver cancer group. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups. The Cox regression model was used to analyze the risk factors for liver cancer in CHB patients and calculate their hazard ratio （HR） and 95% confidence interval （CI）； the variables with statistical significance in the univariate Cox regression analysis were included in the LASSO regression analysis， and then the variables obtained were included in the multivariate Cox regression analysis to establish a predictive model. The nomogram was used to visualize the complex model. The receiver operating characteristic （ROC） curve， index of concordance （C-index）， and the calibration curve were used to assess the predictive efficacy of the model， and the decision curve was used to evaluate the clinical practicability of the nomogram.   Results   A total of 1 479 CHB patients were selected， among whom 58 patients with a confirmed diagnosis of liver cancer， 15 with missing data on testing indicators， and 164 with missing data on important information in the questionnaire were excluded， and finally 1 242 subjects were included in the study. Up to December 31， 2023， there were 67 new cases of liver cancer after a median follow-up time of 7.71 years， and the incidence density of liver cancer was 729.78/100，000 person-years. There were significant differences between the liver cancer group and the non-liver cancer group in age， sex， educational level， liver cirrhosis， duration of liver cirrhosis， history of diabetes mellitus， albumin， total bilirubin （TBil）， direct bilirubin， aspartate aminotransferase， aspartate aminotransferase， gamma-glutamyl transpeptidase （GGT）， and alkaline phosphatase （all P<0.05）. The multivariate Cox regression analysis showed that the increase in age （HR=1.07， 95%CI： 1.05‍ ‍—‍ ‍1.10， P<0.001）， a relatively high level of TBil （HR=1.98， 95%CI： 1.15‍ ‍—‍ ‍3.42， P=0.014）， a relatively high level of GGT （HR=2.41， 95%CI： 1.43‍ ‍—‍ ‍4.08， P=0.001）， and a long duration of liver cirrhosis （HR=1.09， 95%CI： 1.02‍ ‍—‍ ‍1.15， P=0.009） were independent risk factors for liver cancer in CHB patients. A nomogram prediction model was constructed based on the above four indicators， with an area under the ROC curve of 0.790， 0.845， and 0.829， respectively， in predicting the risk of liver cancer in CHB patients at 1， 3， and 5 years， and the bootstrap resampling method was used for internal validation and showed a C-index of 0. 778. The calibration curve showed that the prediction model had good stability， and the decision curve showed that it had certain clinical practicability.   Conclusion   The increase in age， relatively high levels of TBil and GGT， and a long duration of liver cirrhosis are independent risk factors for liver cancer in CHB patients， and the nomogram model constructed based on these factors has a good predictive value and can be used in clinical practice to help develop strategies for the long-term monitoring of liver cancer.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    TRÉPO C, CHAN HL, LOK A. Hepatitis B virus infection[J]. Lancet, 2014, 384( 9959): 2053- 2063. DOI: 10.1016/s0140-6736(14)60220-8.
    [2]
    Global Burden of Disease Liver Cancer Collaboration; AKINYEMIJU T, ABERA S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3( 12): 1683- 1691. DOI: 10.1001/jamaoncol.2017.3055.
    [3]
    CHEN BY, XU HT, DING XY, et al. Serum B7-H2 and interleukin-6 levels in patients with hepatitis B virus-related primary liver cancer and their correlation with prognosis[J]. Trauma Crit Care Med, 2022, 10( 4): 292- 295, 299. DOI: 10.16048/j.issn.2095-5561.2022.04.13.

    陈冰燕, 徐绘婷, 丁翔宇, 等. 乙型肝炎病毒相关原发性肝癌患者血清B7-H2、白细胞介素6水平及其与预后相关性研究[J]. 创伤与急危重病医学, 2022, 10( 4): 292- 295, 299. DOI: 10.16048/j.issn.2095-5561.2022.04.13.
    [4]
    ASRANI SK, DEVARBHAVI H, EATON J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70( 1): 151- 171. DOI: 10.1016/j.jhep.2018.09.014.
    [5]
    SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013[J]. Lancet, 2015, 386( 10003): 1546- 1555. DOI: 10.1016/S0140-6736(15)61412-X.
    [6]
    LIU ZQ, MAO XH, JIANG YF, et al. Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China[J]. Cancer Med, 2019, 8( 12): 5787- 5799. DOI: 10.1002/cam4.2477.
    [7]
    YUEN MF, TANAKA Y, FONG DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B[J]. J Hepatol, 2009, 50( 1): 80- 88. DOI: 10.1016/j.jhep.2008.07.023.
    [8]
    SHERMAN M. Hepatocellular carcinoma: Epidemiology, risk factors, and screening[J]. Semin Liver Dis, 2005, 25( 2): 143- 154. DOI: 10.1055/s-2005-871194.
    [9]
    CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295( 1): 65- 73. DOI: 10.1001/jama.295.1.65.
    [10]
    HE J, CHEN WQ, SHEN HB, et al. China guideline for liver cancer screening(2022, Beijing)[J]. J Clin Hepatol, 2022, 38( 8): 1739- 1758. DOI: 10.3969/j.issn.1001-5256.2022.08.007.

    赫捷, 陈万青, 沈洪兵, 等. 中国人群肝癌筛查指南(2022, 北京)[J]. 临床肝胆病杂志, 2022, 38( 8): 1739- 1758. DOI: 10.3969/j.issn.1001-5256.2022.08.007.
    [11]
    LIANG F, SHA CX, FAN CS, et al. Qidong Chronic Hepatitis B Cohort: Participants enrollment and comparison of baseline characteristics by gender stratification[J]. Chin J Epidemiol, 2017, 38( 11): 1569- 1573. DOI: 10.3760/cma.j.issn.0254-6450.2017.11.026.

    梁枫, 沙春霞, 樊春笋, 等. 启东慢性乙型肝炎临床队列: 建立及基线特征[J]. 中华流行病学杂志, 2017, 38( 11): 1569- 1573. DOI: 10.3760/cma.j.issn.0254-6450.2017.11.026.
    [12]
    KIM BK, AHN SH. Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy[J]. J Formos Med Assoc, 2023, 122( 12): 1238- 1246. DOI: 10.1016/j.jfma.2023.05.029.
    [13]
    LEE HW, AHN SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients[J]. World J Gastroenterol, 2016, 22( 37): 8314- 8321. DOI: 10.3748/wjg.v22.i37.8314.
    [14]
    RAFFETTI E, FATTOVICH G, DONATO F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: A systematic review and meta-analysis[J]. Liver Int, 2016, 36( 9): 1239- 1251. DOI: 10.1111/liv.13142.
    [15]
    WANG Y, WANG M, LI H, et al. A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers[J]. Chin J Cancer Res, 2021, 33( 3): 352- 363. DOI: 10.21147/j.issn.1000-9604.2021.03.07.
    [16]
    YANG HI, YUEN MF, CHAN HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACH-B): Development and validation of a predictive score[J]. Lancet Oncol, 2011, 12( 6): 568- 574. DOI: 10.1016/S1470-2045(11)70077-8.
    [17]
    FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73( 6): 1368- 1378. DOI: 10.1016/j.jhep.2020.07.025.
    [18]
    YU JH, SUH YJ, JIN YJ, et al. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir[J]. Eur J Gastroenterol Hepatol, 2019, 31( 7): 865- 872. DOI: 10.1097/MEG.0000000000001357.
    [19]
    KIM JH, KIM YD, LEE M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol, 2018, 69( 5): 1066- 1073. DOI: 10.1016/j.jhep.2018.07.018.
    [20]
    YANG HI, SHERMAN M, SU J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection[J]. J Clin Oncol, 2010, 28( 14): 2437- 2444. DOI: 10.1200/JCO.2009.27.4456.
    [21]
    WONG VW, CHAN SL, MO F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers[J]. J Clin Oncol, 2010, 28( 10): 1660- 1665. DOI: 10.1200/JCO.2009.26.2675.
    [22]
    LIAW YF, SUNG JJY, CHOW WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351( 15): 1521- 1531. DOI: 10.1056/NEJMoa033364.
    [23]
    LIM YS, HAN S, HEO NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine[J]. Gastroenterology, 2014, 147( 1): 152- 161. DOI: 10.1053/j.gastro.2014.02.033.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (127) PDF downloads(26) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return